AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6127780
Drug: KWD 2131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KWD 2131 (beta-adrenoceptor stimulant)
Trial: 25674699
Drug: Citrulline-Malate (CM)
RxNorm normalized name: citrulline malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline-Malate (CM) 8 g
Trial: 23092310
Drug: Visual aids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual aids depicting multimodal treatment options for colorectal cancer
Trial: 23092310
Drug: Intensive-treatment option
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive-treatment option with clear survival benefit
Trial: 23092310
Drug: Milder treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milder treatment option without survival benefit
Trial: 23092310
Drug: Equally intense
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equally intense treatment options with different timing (neoadjuvant vs. adjuvant) without survival benefit
Trial: 17516768
Drug: Alcohol (0.70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.70 g/kg)
Trial: 11228365
Drug: Edmonston-Zagreb (EZ)
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb (EZ) vaccine, two doses at 6 and 9 months
Trial: 11228365
Drug: Edmonston-Zagreb (EZ)
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb (EZ) vaccine, one dose at 9 months
Trial: 11228365
Drug: Schwarz (SW)
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz (SW) vaccine, two doses at 6 and 9 months
Trial: 11228365
Drug: Schwarz (SW)
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz (SW) vaccine, one dose at 9 months
Trial: 11228365
Drug: Edmonston-Zagreb (EZ)
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb (EZ) vaccine, second dose
Trial: 11228365
Drug: Schwarz (SW)
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz (SW) vaccine, second dose
Trial: 9140636
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation (combination of haloperidol and diazepam, usually 20 mg of each)
Trial: 7957410
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms inhaled oxitropium bromide (OB)
Trial: 7957410
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms inhaled fenoterol (F)
Trial: 7957410
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms inhaled fenoterol (F)
Trial: 1827007
Drug: Isradipine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (1.25 mg twice daily, increased to 2.5 mg if necessary)
Trial: 1827007
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg twice daily, increased to 25 mg if necessary)
Trial: 1827007
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Isradipine and Captopril
Trial: 968036
Drug: External irradiation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External irradiation treatment with total 1,500 rad mid-pelvic dose delivered on five consecutive days
Trial: 30826492
Drug: SSRI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI + vortioxetine (10–20 mg/day)
Trial: 30826492
Drug: vortioxetine (10–20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vortioxetine (10–20 mg/day) + placebo
Trial: 30826492
Drug: vortioxetine (10–20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vortioxetine (10–20 mg/day)
Trial: 17489805
Drug: High-dose botulinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose botulinum toxin A (BTX‐A)
Trial: 17489805
Drug: Low-dose botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose botulinum toxin A (BTX‐A)
Trial: 16189994
Drug: Food purchased
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food purchased from a village with < 10 microg/l arsenic in irrigation water
Trial: 16189994
Drug: Food purchased
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food purchased from markets in the study village with > 100 microg/l arsenic in irrigation water
Trial: 11914107
Drug: alpha-tocopherol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-tocopherol (100 mg/day)
Trial: 11914107
Drug: alpha-carotene +
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-carotene + beta-carotene (15 mg/day)
Trial: 9860093
Drug: Dual-cured resin
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-cured resin composite luting agent
Trial: 9860093
Drug: Chemically cured
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemically cured resin composite luting agent
Trial: 2673340
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ethinyloestradiol gel
Trial: 652210
Drug: Laminaria tents
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria tents used as an adjunct to labor induction
Trial: 31373615
Drug: Screening group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening group (tested for anti-EBV antibodies)
Trial: 25881456
Drug: Telmisartan treatment
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan treatment group (80 mg per day, once daily)
Trial: 25881456
Drug: SG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SG treatment group (5 g each time, 3 times per day)
Trial: 25881456
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SG and telmisartan treatment group (telmisartan 80 mg per day, once daily and SG 5 g each time, 3 times per day)
Trial: 25881456
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SG and telmisartan treatment group
Trial: 9562692
Drug: DTPa‐HB vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa‐HB vaccine administered at 2, 4, and 6 months (group A)
Trial: 9562692
Drug: DTPa‐HB vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa‐HB vaccine administered at 3, 5, and 11 months (group B)
Trial: 1146927
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of very low doses (20 to 40 mug per day) of estrogen with various 19-nor progestins
Trial: 30844728
Drug: Beta-blocker titration
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker titration (bisoprolol and carvedilol)
Trial: 30158384
Drug: NK-104-NP (pitavastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104-NP (pitavastatin calcium) 1 mg
Trial: 30158384
Drug: NK-104-NP (pitavastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104-NP (pitavastatin calcium) 2 mg
Trial: 30158384
Drug: NK-104-NP (pitavastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104-NP (pitavastatin calcium) 4 mg
Trial: 30158384
Drug: NK-104-NP (pitavastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104-NP (pitavastatin calcium) 8 mg
Trial: 20298497
Drug: certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: certolizumab pegol 400 mg (week 0, 2, 4)
Trial: 20298497
Drug: certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: certolizumab pegol 400 mg every 4 weeks until week 24
Trial: 9437314
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.02 mg/ml)
Trial: 9437314
Drug: Gentamicin solution
RxNorm normalized name: gentamicin Injectable Solution
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin solution (0.3%)
Trial: 2698568
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg gallopamil (slow release) twice daily
Trial: 29984439
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline solution pH 7.0
Trial: 29984439
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline solution pH 4.3
Trial: 23245824
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) given immediately after BTX-A injections
Trial: 23245824
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation (ES) given immediately after BTX-A injections
Trial: 16371497
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) at 5.4 J per point, power density 20 mW/cm2
Trial: 2485053
Drug: alpha-human ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-human ANP after acute CE inhibition by enalapril (EN) 20 mg P.O., 4 h before ANP infusion
Trial: 22863328
Drug: 5·0×10(6) cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5·0×10(6) cells per mL every 7 days
Trial: 22863328
Drug: 5·0×10(6) cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5·0×10(6) cells per mL every 14 days
Trial: 22863328
Drug: 0·5×10(6) cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0·5×10(6) cells per mL every 7 days
Trial: 22863328
Drug: 0·5×10(6) cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0·5×10(6) cells per mL every 14 days
Trial: 19995096
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 twice daily
Trial: 19995096
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart three times daily with or without NPH insulin
Trial: 10480584
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release albuterol sulfate
Trial: 7586313
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg intravenous amiodarone
Trial: 7586313
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intravenous amiodarone
Trial: 7586313
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg intravenous amiodarone
Trial: 7586313
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of intravenous amiodarone
Trial: 11026946
Drug: Couple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple therapy
Trial: 31666059
Drug: Generic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic drugs awareness
Trial: 31666059
Drug: Drug-related problems
RxNorm normalized name: Psoriasin Problem Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related problems awareness
Trial: 27816543
Drug: Pharmaceutical assistance
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical assistance programs (PAPs) for smoking cessation medications
Trial: 21844082
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (2 g/d)
Trial: 25708991
Drug: Attention bias
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention bias modification treatment (ABMT)
Trial: 25708991
Drug: Attention bias
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention bias modification treatment (ABMT) delivered in clinic
Trial: 25708991
Drug: Attention bias
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention bias modification treatment (ABMT) delivered at home
Trial: 23917696
Drug: Celiac plexus
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiac plexus block performed first followed by pharmacotherapy (Group I)
Trial: 20701121
Drug: Tpanax Notoginseng
RxNorm normalized name: Panax notoginseng root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tpanax Notoginseng pills (4 g, twice daily)
Trial: 20701121
Drug: Tpanax Notoginseng
RxNorm normalized name: Panax notoginseng root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tpanax Notoginseng pills (4 g, twice daily) and Lornoxicam injection (8 mg, once daily)
Trial: 20701121
Drug: Tpanax Notoginseng
RxNorm normalized name: Panax notoginseng root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tpanax Notoginseng pills (4 g, twice daily), Lornoxicam injection (8 mg, once daily), and Tongmai decoction (200 ml, twice daily)
Trial: 14659344
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with nomegestrol acetate (NOMAC)
Trial: 15758600
Drug: Antithrombotic agents
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic agents
Trial: 1385826
Drug: Patch test
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch test reactions to 11 common organic allergens
Trial: 1385826
Drug: Patch test
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch test control (0.4% phenol and 50% glycerin in 0.9% saline)
Trial: 29121274
Drug: Standard temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard temozolomide with crossover to BEV second-line therapy
Trial: 25271049
Drug: β-blocker use
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker use in prior MI cohort
Trial: 25271049
Drug: β-blocker use
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker use in known atherothrombotic disease cohort
Trial: 25271049
Drug: β-blocker use
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker use in risk factors alone cohort
Trial: 17979860
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTX‐A) injections (3 injections at 0, 6, and 18 months; dose 0.5-2.1 units/kg, mean 1.5 [SD 0.18]; dilution 100 units/0.5 ml)
Trial: 17979860
Drug: Delayed group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed group (2 injections at 6 and 18 months)
Trial: 14717945
Drug: Calcitriol therapy
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol therapy (0.5 microg/48 h) plus oral calcium supplementation (0.5 g/day) for 1 year
Trial: 11591835
Drug: Clomethiazole (68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomethiazole (68 mg/kg IV over 24 hours)
Trial: 7827649
Drug: 3 different
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 different drug regimes
Trial: 2683908
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg administered sublingually)
Trial: 18717710
Drug: Classic ketogenic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classic ketogenic diet (KD) with glucose (60 g/day)
Trial: 14698679
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) 100 microg bolus injection
Trial: 14698679
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) 150 microg infusion
Trial: 1573045
Drug: Buspirone 5
RxNorm normalized name: busPIRone 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 5 mg three times a day for the first week, then 10 mg in the morning, 5 mg in the afternoon, and 5 mg in the evening for the next three weeks.
Trial: 1573045
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg three times a day for all 4 weeks.
Trial: 1573045
Drug: Driving performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Driving performance test after each treatment week.
Trial: 3993625
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (DTIC, DTIC/CCNU/vincristine)
Trial: 3993625
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no further treatment after surgery)
Trial: 26638185
Drug: Control (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (weekly mailings)
Trial: 22693238
Drug: Caffeine (CAFF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAFF) 3 mg/kg body mass
Trial: 22693238
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate (SB) 0.3 g · kg⁻¹ · BM⁻¹
Trial: 18332706
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion at 2.5-3.0 g/kg/day
Trial: 18332706
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion at 4.0 g/kg/day
Trial: 16260639
Drug: Clopidogrel 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 900 mg
Trial: 10381666
Drug: Corticosteroids (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (starting doses of 60-1000 mg per day, reduced to 40-50 mg per day after 4-6 weeks)
Trial: 10381666
Drug: Corticosteroids (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (conventional dose 60-80 mg per day vs very high doses 200-1000 mg per day)
Trial: 10381666
Drug: Corticosteroids (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (various doses)
Trial: 7594326
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg and AMPC 1,500 mg
Trial: 7594326
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg alone
Trial: 120339
Drug: AMCA (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMCA (160 mg/extraction site)
Trial: 31280035
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) combined with medication
Trial: 23224592
Drug: Parental trait
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental trait anxiety in treatment responders